Pharmacosmos sees big potential in million-dollar acquisition

Family-owned Pharmacosmos wants to grow, which is why the company has paid up to USD 225m for US-based Abfero Pharmaceuticals last week, also acquiring its lead candidate SP-420 that Pharmacosmos says has a promising future ahead.

Photo: Pharmacosmos / PR

Pharmacosmos took out the the big checkbook last week, when the family-owned company, which is based in Denmark, acquired the privately owned Boston-based business Abfero Pharmaceuticals.

The price tag may end up as much as USD 225m – when combining up-front and milestone payments, royalties, and more. The US-based company works within iron overload therapy, which is also the focus of Pharmacosmos, but the agreement's details are being kept under wraps.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs